Welcome to KAHR Medical
The mission at KAHR Medical is to develop novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases.
The company's drug development pipeline is built around 'Dual Signaling Proteins (DSP)' -
a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another.  Read More...


Animated clip: DSP technology in autoimmune

Animated clip: DSP technology in cancer

News & Events
September 11, 2013: KAHR Medical raise additional $2.35M

February 4, 2013: KAHR Medical Granted U.S. Patent Approval for One of its Lead Products in Development, KAHR-101

June 26, 2012: KAHR Medical and Cobra Biologics extend their partnership to develop both KAHR-101 and KAHR-102